Prediction of Clinical Response After 1 Year of Infliximab Therapy in Rheumatoid Arthritis Based on Disease Activity at 3 Months: Posthoc Analysis of the RISING Study* Takeuchi T, Miyasaka N, Inui T, Yano T, Yoshinari T, Abe T, et al. Prediction of clinical response after 1 year of infliximab therapy in rheumatoid arthritis based on disease activity at 3 months: posthoc analysis of the RISING study. J Rheumatol 2015;42:599–607. In Table 3A, column 1 was incorrectly indented. The corrected table appears here. We regret the error.
Table 3. Independent-associated factors with disease activity, REM/LDA, HAQ score, and functional remission at W54.
Multiple linear regression analysis of SDAI, DAS28-CRP, and HAQ score at W54.
Multiple logistic regression analysis of achievement of REM/LDA and functional remission at W54.
Footnotes
-
↵* This correction is to the First Release version only, published online February 15, 2015.
